Merck KGaA (MKKGY)
OTCMKTS
· Delayed Price · Currency is USD
26.36
-0.30 (-1.13%)
Jun 5, 2025, 3:56 PM EDT
Merck KGaA Revenue
Merck KGaA had revenue of 5.28B EUR in the quarter ending March 31, 2025, with 3.13% growth. This brings the company's revenue in the last twelve months to 21.32B, up 2.38% year-over-year. In the year 2024, Merck KGaA had annual revenue of 21.16B with 0.78% growth.
Revenue (ttm)
21.32B EUR
Revenue Growth
+2.38%
P/S Ratio
2.49
Revenue / Employee
361.17K EUR
Employees
59,020
Market Cap
57.45B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 21.16B | 163.00M | 0.78% |
| Dec 31, 2023 | 20.99B | -1.24B | -5.57% |
| Dec 31, 2022 | 22.23B | 2.55B | 12.93% |
| Dec 31, 2021 | 19.69B | 2.15B | 12.28% |
| Dec 31, 2020 | 17.53B | 1.38B | 8.56% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo Inc. | 1.73B |
| Veradigm | 588.02M |
| Tian'an Technology Group | 1.78M |
| Elite Pharmaceuticals | 70.00M |
| Glass House Brands | 215.62M |
| Northwest Biotherapeutics | 1.47M |
| American Oncology Network | 1.76B |
| Silence Therapeutics | 27.70M |
Merck KGaA News
- 8 days ago - Pimicotinib Demonstrates Best-in-Class Potential with Significant Efficacy and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumor - Benzinga
- 10 days ago - Merck Foundation Chairman and CEO Meet Nigeria First Lady to Underscore Their Long-Term Commitment to Transform Patient Care Landscape in the Country - Business Upturn
- 15 days ago - EMD Serono Presents Positive Phase 2 Data for Enpatoran Demonstrating Reduction in Disease Activity in Patients with Cutaneous Lupus Erythematosus (CLE) and Systemic Lupus Erythematosus (SLE) with Active Lupus Rash - Benzinga
- 21 days ago - Merck KGaA 2025 Q1 - Results - Earnings Call Presentation - Seeking Alpha
- 21 days ago - Merck KGaA (MKGAF) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 21 days ago - Merck KGaA Non-GAAP EPS of €2.12, revenue of €5.28B; updates FY25 outlook - Seeking Alpha
- 22 days ago - Merck KGaA Cuts Outlook Amid Macroeconomic Challenges - WSJ
- 22 days ago - Merck KGaA strikes more cautious tone on 2025 adj profit - Reuters